Skip to main content

Top navigation

  • GSA Award
  • For Veterans
  • HCP Portal
  • Pay My Bill Online
  • Contact Us
  • +1 844 396 7663
Bio-Techne Exosome logo

Main navigation

  • Physicians
    • How to Order the ExoDx™ Prostate Test
    • ExoDx™ Prostate Test: At-Home Collection Kit
    • ExoDx™ Prostate Test
    • Challenge of Prostate Cancer
    • Physician FAQs
    • What are Exosomes
    • Publications and Abstracts
    • mpMRI + ExoDx Prostate Test
  • Patients
    • The ExoDx Prostate Test
    • How to Order the ExoDx™ Prostate Test
    • Physician Finder
    • Understanding PSA Levels
    • Elevated PSA Levels
    • Normal PSA Levels & PSA Levels by Age
    • About Prostate Cancer
    • ZERO - The End of Prostate Cancer
    • Patient FAQs
    • ExoCARES Program
  • Pharma Services
    • Working with Us
    • Biomarker Discovery
    • Assay Development
    • Exosome Enrichment Capabilities
    • Companion Diagnostics (CDx) and Clinical Trial Support
  • Our Technology
    • Our Technology
    • Sensitivity to RNA/DNA
    • Extraction Procedures
    • Superiority to cfDNA and CTCs
  • News & Resources
    • Literature
    • Press
    • Webinars
    • Events
    • Newsletters

Top navigation

  • GSA Award
  • For Veterans
  • HCP Portal
  • Pay My Bill Online
  • Contact Us
  • +1 844 396 7663

An Integrated Biomarker and MRI Risk Assessment Approach to Prostate Cancer Diagnosis

Webinar May 12, 2023

Prostate cancer guidelines seek to optimize diagnosis while minimizing over-diagnosis. This webinar explores integrating biomarkers like ExoDx Prostate Test with MRI imaging for better risk assessment in patients considering biopsy.

 

Listen to the podcast: An Integrated Biomarker and MRI Risk Assessment Approach to Prostate Cancer Diagnosis

(844) 396-7663
exosomedx.info@bio-techne.com
266 Second Ave, Suite 200
Waltham, MA 02451

Footer menu

  • About Bio-Techne
  • Management Team
  • Careers
  • Investors
  • Corporate Responsibility
  • Accreditation and Licensure

Social navigation

  • Facebook
  • Twitter
  • LinkedIn

The ExoDx Prostate Test was evaluated and its performance characteristics determined by Exosome Diagnostics, Inc. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988 as qualified to perform high complexity clinical testing. CLIA number: 22D2093470.  Exosome Diagnostics and ExoDx are registered trademarks of Exosome Diagnostics, Inc.

© 2025 ExoDx

Bottom footer navigation

  • Privacy Policy